Training program for childhood blood cancers
Official title: Childhood Hematological Malignancies Training Program
Funded at St. Jude Children's Research Hospital · NIH-10849301 · Data updated 2026-11-12
This program is all about helping new scientists learn how to create better treatments for kids with blood cancers by using the latest genetic discoveries, so they can improve how these cancers are diagnosed and treated.
Quick facts
| Grant type | Training grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Jude Children's Research Hospital NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project start | August 8, 2019 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $244,925 |
| NIH project number | 2T32CA236748-06 |
| Project ID | NIH-10849301 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research are children diagnosed with hematological malignancies and their families seeking advanced treatment options.
✕Less likely to help
Patients with non-hematological cancers or those who do not have access to the training program may not receive any benefit from this research.
What this research studies
This program focuses on training new scientists to understand and develop better treatments for childhood hematological malignancies, which are the most common type of cancer in children. It aims to translate genetic discoveries into practical insights that can improve diagnosis and therapy for these cancers. The program provides hands-on experience in genomic analysis and experimental modeling, preparing trainees to become leaders in this critical field of pediatric oncology.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for children diagnosed with hematological malignancies.
How similar studies have gone: Other training programs focused on pediatric cancers have shown success in advancing treatment and understanding of these diseases, making this approach promising.
Where this research is happening
-
St. Jude Children's Research Hospital
Memphis, United States Active
Researchers
- Principal investigator: Mullighan, Charles G. — St. Jude Children's Research Hospital
- Study coordinator: Mullighan, Charles G.
Related research
Other NIH-funded projects on the same topics.
-
Engineering CD19 mimotopes to boost and broaden CD19-CAR T cell therapy
A patient-focused look at improving existing CD19-CAR T cell therapy so more people with blood cancers might benefit.
-
Disrupting BM niches and boostingCAR-T therapy in blood cancers
A program at Washington University is developing better ways to collect stem cells for transplantation, reduce graft-versus-host disease, and improve CAR-T cell therapies for blood cancers.
-
Time-restricted eating to help fatigue in blood cancer survivors
A 12-week program tests whether eating within a daytime 10-hour window can reduce fatigue in people who have survived blood cancers.
-
Optimizing Blood Stem Cell Transplants for Blood C cancers and related diseases
This grant supports improving how stem cell transplants are collected and given, with the goal of better outcomes and fewer side effects for people with blood cancers and some autoimmune or inherited conditions.
-
Tailoring a fun, tech-assisted mental health program for teens and young adults with blood cancers
A planning grant to adapt a technology-based cognitive behavioral therapy program to meet the unique needs of adolescents and young adults with hematologic cancers.
-
Off-the-Shelf Immune Cells to Fight Childhood Blood Cancers
A US study from Minnesota is exploring ready-to-use immune cells to treat kids with leukemia that may not respond to standard therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.